Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A circulating tumor dna detection system and its application for screening minimal residual lesions after colorectal cancer surgery and predicting recurrence risk

A detection system and colorectal cancer technology, applied in the field of circulating tumor DNA detection, can solve the problems of inability to accurately guide adjuvant chemotherapy, poor risk stratification tool evaluation, difficulty in finding colorectal cancer minimal residual lesions, etc., and achieve recurrence prediction Risk, guiding postoperative adjuvant therapy, and the effect of convenient detection process

Active Publication Date: 2022-06-07
SUN YAT SEN UNIV CANCER CENT
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to solve the problem that the existing risk stratification tools for colorectal cancer patients after radical resection are not effective in evaluating, it is difficult to find small residual lesions after radical resection of colorectal cancer, and it is impossible to accurately guide adjuvant chemotherapy. Detecting deficiencies of ctDNA technology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A circulating tumor dna detection system and its application for screening minimal residual lesions after colorectal cancer surgery and predicting recurrence risk
  • A circulating tumor dna detection system and its application for screening minimal residual lesions after colorectal cancer surgery and predicting recurrence risk
  • A circulating tumor dna detection system and its application for screening minimal residual lesions after colorectal cancer surgery and predicting recurrence risk

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Circulating tumor DNA detection

[0042] 1. Sample source: 240 colorectal cancer patients who received radical surgery were treated according to current guidelines and followed up regularly.

[0043] 2. Sample collection: collect tumor tissue samples and peripheral blood leukocyte samples from patients after surgery, 3-7 days after surgery, 6 months after surgery, 9 months after surgery, 12 months after surgery, and 15 months after surgery. Plasma samples were taken consecutively from the patients after 18 months, 21 months after surgery, and 24 months after surgery.

[0044] 3. Detection method:

[0045] 1. High-throughput sequencing: Obtain surgically resected tumor tissue specimens and peripheral blood leukocyte samples from colorectal cancer patients, extract cellular genomic DNA, construct a sequencing library, and then use a next-generation sequencing gene panel panel containing 425 cancer-related genes ( panel) for targeted capture, and the specific ...

Embodiment 2

[0065] Example 2: Continuous blood collection to detect circulating tumor DNA to identify tumor recurrence

[0066] Based on Example 1, colorectal cancer patients with serial postoperative plasma samples (≥3) and sufficient follow-up time (≥24 months or tumor recurrence) were included to analyze whether serial blood sampling to detect circulating tumor DNA can early identify tumor recurrence.

[0067] Follow up to observe whether the ctDNA-positive patients determined by the detection system of the present invention eventually have tumor recurrence, and calculate the time from the first positive ctDNA detection to tumor recurrence, which is the advance of ctDNA detection compared with conventional imaging methods in predicting tumor recurrence. time.

[0068] like figure 2 As shown in A, the parameters of the COX proportional hazards model calculated based on the patient's follow-up survival data are: hazard ratio ln[h(t,X) / h 0 (t)]=32.02*ctDNA, patients with positive circu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a circulating tumor DNA detection system for screening the existence of postoperative minimal residual lesions in colorectal cancer patients and predicting the risk of recurrence. The detection system includes a colorectal cancer tissue gene mutation screening module, a plasma cell-free DNA gene mutation analysis module, and a circulating tumor DNA status judgment module. The system uses the same next-generation sequencing gene panel to detect primary tumor tissue and plasma cell-free DNA, and considers all mutations detected in the patient's primary tumor tissue, rather than being limited to individual gene mutations, which is more comprehensive. This system can be applied to the dynamic and real-time monitoring of circulating tumor DNA, and can be used to assess the residual status of minimal residual lesions after radical resection of colorectal cancer, predict the risk of recurrence, and guide postoperative treatment decisions.

Description

technical field [0001] The invention belongs to the technical field of tumor prognosis assessment, and in particular relates to the detection of circulating tumor DNA and its application. Background technique [0002] Colorectal cancer is the third most common cancer worldwide, with more than 19 million new cases each year. Colorectal cancer is also the second leading cause of cancer-related death, with a five-year mortality rate of approximately 40%. With screening based on serum carcinoembryonic antigen and colonoscopy, an increasing number of patients can now be diagnosed before distant metastases develop, for which surgical resection is the optimal treatment modality. However, a considerable proportion of patients still experience recurrence after radical resection. Minimal residual disease (MRD) is considered to be the main source of disease recurrence, but MRD is often invisible on imaging. Adjuvant chemotherapy for three to six months after surgery for colorectal c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G16B20/50C12Q1/6869C12Q1/6886G16B20/30
CPCG16B20/50G16B20/30C12Q1/6886C12Q1/6869C12Q2600/156C12Q2535/122
Inventor 徐瑞华王峰陈功邵阳
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com